Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Condition: Esophageal Squamous Cell Carcinoma Interventions: Drug: Carrelizumab; Drug: Paclitaxel injection; Drug: Cisplatin; Radiation: Concurrent chemoradiotherapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
Condition: Esophageal Carcinoma Interventions: Drug: Nimotuzumab; Drug: Tigio; Radiation: Concurrent radiation therapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Follow-up Strategy for Esophageal Cancer Patients
Condition: Esophagus Cancer Intervention: Other: follow-up with different time intervals Sponsor: Sun Yat-sen University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Adenocarcinoma
Conditions: Adenocarcinoma Esophagus; Locally Advanced Adenocarcinoma; Siewert Type I Adenocarcinoma of Esophagogastric Junction; Siewert Type II Adenocarcinoma of Esophagogastric Junction Interventions: Drug: Vactosertib; Drug: Standard of Care Chemotherapy; Radiation: Concurrent Radiation Sponsor: Jennifer Eva Selfridge Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Condition: Esophageal Squamous Cell Carcinoma Interventions: Drug: Carrelizumab; Drug: Paclitaxel injection; Drug: Cisplatin; Radiation: Concurrent chemoradiotherapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
Condition: Esophageal Carcinoma Interventions: Drug: Nimotuzumab; Drug: Tigio; Radiation: Concurrent radiation therapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Follow-up Strategy for Esophageal Cancer Patients
Condition: Esophagus Cancer Intervention: Other: follow-up with different time intervals Sponsor: Sun Yat-sen University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Adenocarcinoma
Conditions: Adenocarcinoma Esophagus; Locally Advanced Adenocarcinoma; Siewert Type I Adenocarcinoma of Esophagogastric Junction; Siewert Type II Adenocarcinoma of Esophagogastric Junction Interventions: Drug: Vactosertib; Drug: Standard of Care Chemotherapy; Radiation: Concurrent Radiation Sponsor: Jennifer Eva Selfridge Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Condition: Esophageal Squamous Cell Carcinoma Interventions: Drug: Carrelizumab; Drug: Paclitaxel injection; Drug: Cisplatin; Radiation: Concurrent chemoradiotherapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
Condition: Esophageal Carcinoma Interventions: Drug: Nimotuzumab; Drug: Tigio; Radiation: Concurrent radiation therapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Follow-up Strategy for Esophageal Cancer Patients
Condition: Esophagus Cancer Intervention: Other: follow-up with different time intervals Sponsor: Sun Yat-sen University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Adenocarcinoma
Conditions: Adenocarcinoma Esophagus; Locally Advanced Adenocarcinoma; Siewert Type I Adenocarcinoma of Esophagogastric Junction; Siewert Type II Adenocarcinoma of Esophagogastric Junction Interventions: Drug: Vactosertib; Drug: Standard of Care Chemotherapy; Radiation: Concurrent Radiation Sponsor: Jennifer Eva Selfridge Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Condition: Esophageal Squamous Cell Carcinoma Interventions: Drug: Carrelizumab; Drug: Paclitaxel injection; Drug: Cisplatin; Radiation: Concurrent chemoradiotherapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
Condition: Esophageal Carcinoma Interventions: Drug: Nimotuzumab; Drug: Tigio; Radiation: Concurrent radiation therapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Follow-up Strategy for Esophageal Cancer Patients
Condition: Esophagus Cancer Intervention: Other: follow-up with different time intervals Sponsor: Sun Yat-sen University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
